Suppr超能文献

微小RNA-30a表达下调通过激活Beclin-1介导的自噬促进骨肉瘤细胞的化疗耐药。

MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy.

作者信息

Xu Ruida, Liu Shuzhong, Chen Haihong, Lao Lifeng

机构信息

Department of Orthopaedic Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, P.R. China.

出版信息

Oncol Rep. 2016 Mar;35(3):1757-63. doi: 10.3892/or.2015.4497. Epub 2015 Dec 18.

Abstract

Autophagy has been recognized as an important element of tumor cell migration, invasion, and chemo-resistance, and our previous results showed that Beclin-1-mediated autophagy contributed to osteosarcoma chemoresistance. However, the regulating mechanism of autophagy is still unclear. In this study, our aim was to clarify microRNA (miRNA)-related mechanisms underlying Beclin-1-mediated autophagy followed by chemotherapy in osteosarcoma. First, miRNA screening using qRT-PCR identified that miR-30a was significantly reduced in Dox-resistant osteosarcoma cells. Second, the autophagy activity in Dox-resistant increased while miR-30a expression reduced after chemotherapy agents as indicated by the enhanced expression of Beclin-1, the increased conversion of microtubule-associated protein LC3-I to LC3-II. Furthermore, overexpression of miR-30a significantly promoted chemotherapy-induced apoptosis and reduced autophagy activity responding to chemotherapy. Moreover, rapamycin, an autophagy promoter was able to partly reverse the effect of miR-30a and Luciferase reporter assay identified that miR-30a directly binds to the 3'-UTR of Beclin-1 gene, which further confirmed that miR-30a reduced chemoresistance via suppressing Beclin-1-mediated autophagy. Collectively these results indicate miR-30a and its downstream target gene Beclin-1 can be used in treatment of osteosarcoma chemo-resistance in the future.

摘要

自噬已被认为是肿瘤细胞迁移、侵袭和化疗耐药的一个重要因素,我们之前的结果表明,Beclin-1介导的自噬促成骨肉瘤的化疗耐药。然而,自噬的调控机制仍不清楚。在本研究中,我们的目的是阐明骨肉瘤中Beclin-1介导的自噬及后续化疗相关的微小RNA(miRNA)机制。首先,使用qRT-PCR进行miRNA筛选,结果显示耐多柔比星骨肉瘤细胞中miR-30a显著降低。其次,化疗药物处理后,耐多柔比星细胞中的自噬活性增加,而miR-30a表达降低,这表现为Beclin-1表达增强、微管相关蛋白LC3-I向LC3-II的转化增加。此外,miR-30a过表达显著促进化疗诱导的凋亡,并降低对化疗的自噬活性。而且,自噬促进剂雷帕霉素能够部分逆转miR-30a的作用,荧光素酶报告基因检测确定miR-30a直接与Beclin-1基因的3'-UTR结合,这进一步证实miR-30a通过抑制Beclin-1介导的自噬降低化疗耐药性。总体而言,这些结果表明miR-30a及其下游靶基因Beclin-1未来可用于治疗骨肉瘤的化疗耐药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验